Salud financiera de hoja de balance de Brooks Laboratories

Salud financiera controles de criterios 4/6

Brooks Laboratories tiene un patrimonio de accionistas total de ₹592.1M y una deuda total de ₹71.8M, lo que sitúa su ratio deuda-patrimonio en 12.1%. Sus activos y pasivos totales son ₹911.2M y ₹319.2M respectivamente. El BAIT de Brooks Laboratories es de ₹22.0M, por lo que su ratio de cobertura de intereses es de 3. Tiene efectivo e inversiones a corto plazo que ascienden a ₹8.1M.

Información clave

12.1%

Ratio deuda-patrimonio

₹71.79m

Deuda

Ratio de cobertura de intereses	3x
Efectivo	₹8.08m
Patrimonio	₹592.09m
Total pasivo	₹319.16m
Activos totales	₹911.24m

Actualizaciones recientes sobre salud financiera

Recent updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Feb 22

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₹378.6M) de BROOKS superan a sus pasivos a corto plazo (₹287.0M).

Pasivo a largo plazo: Los activos a corto plazo de BROOKS (₹378.6M) superan a sus pasivos a largo plazo (₹32.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (10.8%) de BROOKS se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de BROOKS ha pasado de 29.4% a 12.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BROOKS tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: BROOKS tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.4% cada año

Salud financiera de hoja de balance de Brooks Laboratories

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Recent updates

Insider recently sold ₹66m worth of stock

Second quarter 2025 earnings released: ₹1.51 loss per share (vs ₹0.64 loss in 2Q 2024)

Brooks Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024

Brooks Laboratories Limited Announces Cessation of Sonia Gupta as Independent Director

Brooks Laboratories Limited Announces Board Appointments

New minor risk - Share price stability

High number of new and inexperienced directors

Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024

First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)

Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)

Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)

Brooks Laboratories Limited Announces Director Appointments

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

New minor risk - Shareholder dilution

Brooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)

First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)

Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Brooks Laboratories Limited Appoints Durga Shankar Maity as Additional Director

Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)

Brooks Laboratories Limited Appoints Kaushalya Singh as a Whole Time Director of the Company

Brooks Laboratories Limited Announces Resignation of Atul Ranchal as Chairman, Effective on November 23, 2022

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Brooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)

Jyoti Sancheti Resigns as Company Secretary & Compliance Officer of Brooks Laboratories Limited, with Effect from 7 June, 2022

Brooks Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Brooks Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)

Less than half of directors are independent

Technical Director & Whole Time Director Suresh Garg has left the company

Insufficient new directors

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)

Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)

New 90-day low: ₹58.60

Brooks Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

New 90-day high: ₹73.20

New 90-day high: ₹71.75

New 90-day high: ₹68.75

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Brooks Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

First quarter earnings released

New 90-day high: ₹44.65

Brooks Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Full year earnings released - ₹13.84 loss per share

New 90-day high - ₹37.80

Full year earnings released - ₹13.84 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera